Recruiting

Bosulif

Sponsor:

Pfizer

Code:

NCT06297161

Conditions

Chronic Leukemia Myelogenous

Eligibility Criteria

Sex: All

Age: 20+

Healthy Volunteers: Not accepted

Interventions

Bosulif

Study Details

Brief summary:

The purpose of this study is to look at how safe and effective is bosulif in routine clinical practice.

This study is seeking for participants who are:

1. Patients who are being treated\* or will be treated with Bosulif according to it's local product document under routine clinical practice (\*Patients who initiated Bosulif treatment within one year before consent)
2. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

All participants in this study will receive bosulif. All participants who have entered this study should meet the usual prescribing criteria for bosulif as per the LPD. The participants will be treated with bosulif under routine clinical practice in Korea.

The study will look at the experiences of people receiving the study medicine. This will help to see if the study medicine is safe and effective.

In this study all treatment and checking of the patients will be done as per the study doctor. The study can be performed in Korean health care centers where bosulif is prescribed to treat CML after the patients have agreed to take part in the study.

Conditions

Chronic Leukemia Myelogenous

Study ID

NCT06297161

Start date

Jan 20, 2025

Status verified date

Apr, 2026

Completion date

Jun 1, 2028

Anticipated

Primary completion date

Jun 1, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 20+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Patients who are being treated\* or will be treated with Bosulif according to it's local product document under routine clinical practice (\*Patients who initiated Bosulif treatment within one year before consent)
2. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion Criteria:

\- Patients to whom bosulif is contraindicated as per the local labeling- Any patients (or a legally acceptable representative) who does not agree that Pfizer and companies working with Pfizer use his/her information

Study Design

Enrollment

600 participants

Anticipated

Interventions and Outcome Measures

Arms

Patients with newly diagnosed CP Ph+ CML

Patients newly-diagnosed with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML)

Interventions

Bosulif

chronic myelogenous leukemia patients

Primary outcome measure

  • Incidence of AEs [ Time Frame: From the date of bosulif treatment completion until index period (Between 30 Dec 2022 and 29 Dec 2028) ]

Central Contacts and Locations

Central contacts

Locations

Pfizer New York

Recruiting

New York, New York, United States, 10001

More Information

Sponsor

Pfizer

Last update posted

Apr 14, 2026

Last verified

Apr, 2026

Keywords

  • Philadelphia chromosome-positive (Ph+)

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Pfizer on 2026-04-14.